Phospho-specific antibodies’ typical purpose is to enable researchers to detect changes in proteins. They will exclusively bind to the amino acid sequence on a protein that has been phosphorylated (which is both a physical & chemical change) and do not bind to the same amino acid sequence on said protein if it lacks said phosphorylation. This aids in being able to clearly see and understand the data produced from this particular protein modification.
IF (Immunofluorescence) (P-peptide-+ Immunofluorescence analysis of HepG2 cells, using A-RAF (Phospho-Tyr301/302) antibody.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using A-RAF (Phospho-Tyr301/302) antibody. Western blot analysis of extracts from HeLa cells, treated with PMA (125ng/ml, 30mins), using A-RAF (Phospho-Tyr301/302) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human heart tissue using PKD1/2/3/PKC mu (Phospho-Ser738+Ser742) antibody. Western blot analysis of extracts from A549 cells treated with PMA (125ng/ml, 30mins), and HT-29 cells treated with serum (20%, 15mins), using PKD1/2/3/PKC mu (Phospho-Ser738+Ser742) antibody.)
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human colon carcinoma tissue using PFKFB2 (Phospho-Ser483) antibody. Western blot analysis of extracts from 293 cells, treated with Heat shock, using PFKFB2 (Phospho-Ser483) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (P-peptide-+ Immunofluorescence analysis of HeLa cells, using PPAR-beta (Phospho-Thr1457) antibody.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human heart tissue using PPAR-beta (Phospho-Thr1457) antibody. Western blot analysis of extracts from HuvEc cells, treated with Serum (20%, 30mins), using PPAR-beta (Phospho-Thr1457) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (P-peptide-+ Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using DDX5/DEAD-box Protein 5 (Phospho-Tyr593) antibody. Immunofluorescence analysis of HeLa cells, using DDX5/DEAD-box Protein 5 (Phospho-Tyr593) antibody.)
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of the extracts from NIH/3T3 cells using HDAC5 (Ab-498) Antibody and HDAC5 (Phospho-Ser498) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded breast carcinoma, using HDAC5 (Phospho-Ser498) Antibody. Left: Untreated; Right: Treated with synthesized phosphopeptide.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (P-peptide-+ Immunofluorescence analysis of NIH/3T3 cells, using Bcr (Phospho-Tyr360) antibody.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using Bcr (Phospho-Tyr360) antibody. Western blot analysis of extracts from COS7 cells, using Bcr (Phospho-Tyr360) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human heart tissue using Pin1 (Phospho-Ser16) antibody. Western blot analysis of extracts from COS-7 cells, treated with insulin (0.01U/ml, 15mins), using Pin1 (Phospho-Ser16) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using SAPK/JNK (Phospho-Tyr185) antibody. Western blot analysis of extracts from HepG2 cells, treated with nocodazole (1ug/ml, 16hours), using SAPK/JNK (Phospho-Tyr185) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from Jurkat cells treated with PMA. Left: Using ERK1/2 (phospho-Thr202/Tyr204) antibody. Right: Using the same antibody preincubated with synthesized peptide.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ERK1/2 (phospho-Thr202/Tyr204).)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from A2780 cells (Lane 1 and 2) and MDA-MB-435 cells (Lane 3), using CDK2 (phospho-Thr160) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using CDK2 (phospho-Thr160) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
WB (Western Blot) (Western blot analysis of extracts from HUVEC cells, using ICAM-1 (Ab-512) Antibody and ICAM-1 (Phospho-Tyr512) Antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (UV-+ Western blot analysis of extracts from NIH/3T3 cells using c-Jun (phospho-Ser63) antibody)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using c-Jun (phospho-ser63) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extract from Jurkat cells, untreated or treated with PMA (1ng/ml, 5min), using Pyk2 (Ab-402) antibody and Pyk2 (phospho-Tyr402) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using Pyk2 (phospho-Tyr402) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from K562 cells treated with UV (20min), using BRCA1 (phospho-Ser1423) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using BRCA1 (phospho-Ser1423) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extract from SW 626 cells, using beta-Catenin (Ab-37) antibody and beta-Catenin (phospho-Ser37) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using beta-Catenin (phospho-Ser37) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from MDA-MB-231 cells, untreated or treated with TNF-alpha (20ng/ml, 10min) using NF-kappaB p65 (Ab-529) antibody and NF-kappaB p65 (phospho-Ser529) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using NF-kappaB p65 (Phospho-Ser529) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from Hela cells untreated or treated with Heat Shock or UV, using HSP27 (Ab-82) antibody and HSP27 (Phospho-Ser82) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using HSP27 (phospho-Ser82) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from ovary cancer cells using Myc (phospho-Thr58) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Myc (phospho-Thr58) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using JAK2 (phospho-Tyr221) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from HeLa cells using JunB (phospho-Ser259) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma using JunB (phospho-Ser259) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from MCF7 cells, using HSF1 (phospho-Ser303) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using HSF1 (phospho-Ser303) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extract from HeLa cells untreated or treated with TNF-alpha using NF-kappaB p105/p50 (phospho-Ser907) antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NF-kappaB p105/p50 (phospho-Ser907) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (P-peptide-+ Western blot analysis of extracts from HeLa cells, using Kir6.2 (Phospho-Thr224) antibody. Immunofluorescence analysis of HuvEc cells, using Kir6.2 (Phospho-Thr224) antibody.)
Affinity-purified fromrabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using OSR1 (Phospho-Thr185) antibody. Western blot analysis of extracts from HepG2 cells, treated with serum (20%, 15mins), using OSR1 (Phospho-Thr185) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Application Data (P-peptide-+Immunohistochemistry analysis of paraffin-embedded human lung carcinoma using CDC25A (Phospho-Ser75) Antibody.Western blot analysis of extracts from HuvEc, using CDC25A (Phospho-Ser75) Antibody.)
Application Data (p16-INK4a (Phospho-Ser152) antibody reacts with epitope-specific phosphopeptide and corresponding non-phosphopeptide. The absorbance readings at 450 nM are shown in the ELISA figure.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using p16-INK4a (Phospho-Ser152) antibody. Western blot analysis of extracts from HeLa cells, treated with EPO (20U/ml, 15mins), using p16-INK4a (Phospho-Ser152) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Peptide-+ Western blot analysis of extracts from HT-29 cells, using IRS-1 (Phospho-Ser312) antibody. Immunofluorescence analysis of HeLa cells, using IRS-1 (Phospho-Ser312) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody againstnon-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Application Data (P-peptide - +Immunofluorescence analysis of A549 cells, using Akt (Phospho-Ser473) Antibody)
Application Data (P-peptide-+Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using Akt (Phospho-Ser473) Antibody.Western blot analysis of extracts from K562, using Akt (Phospho-Ser473) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using Mnk1 (Phospho-Thr385) antibody. Western blot analysis of extracts from COLO cells, treated with PMA (125ng/ml, 30mins), using Mnk1 (Phospho-Thr385) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human liver carcinoma tissue using Mst1/2 (Phospho-Thr183) antibody. Western blot analysis of extracts from 293 cells, treated with H2O2 (100uM, 15mins), using Mst1/2 (Phospho-Thr183) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from HeLa cells treated with Adriamycin (0.5ng/ml, 24hours), using HSL (Phospho-Ser855/554) antibody (#A0074).)
IHC (Immunohistochemistry) (P-peptide-+ Immunohistochemical analysis of paraffin-embedded human colon carcinoma tissue using HSL (Phospho-Ser855/554) antibody (#A0074).)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using BLNK (Phospho-Tyr84) antibody. Western blot analysis of extracts from K562 cells, treated with starved (24hours), using BLNK (Phospho-Tyr84) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody againstnon-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using TOB1 (Phospho-Ser164) antibody. Western blot analysis of extracts from HT-29 cells, treated with serum (20%, 15mins), using TOB1 (Phospho-Ser164) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatographyusing non-phosphopeptide corresponding to the phosphorylation site.
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using UBF (Phospho-Ser484) antibody. Western blot analysis of extracts from HeLa cells, treated with calyculinA (50ng/ml, 30mins), using UBF (Phospho-Ser484) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from K562 cells using GATA-1 (phospho-Ser142) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using GATA-1 (phospho-Ser142) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using JAK2 (phospho-Tyr1007) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from K562 cells untreated or treated with 10% serum after 48 hours of starvation, using Rb (phospho-Ser795) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using Rb (phospho-Ser795) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extract from HeLa cells treated with TNF-alpha and using NF-kappaB p105/p50 (phospho-Ser337) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NF-kappaB p105/p50 (phospho-Ser337) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extract from HT-29 cells untreated or treated with Doxorubicin (1mM, 30min), using ADD1 (Ab-726) antibody and ADD1 (Phospho-Ser726) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue using ADD1 (Phospho-Ser726) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from K562 cells using ASK1 (phospho-Ser83) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ASK1 (phospho-Ser83) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using HER2 (phospho-Tyr1248) antibody.)
ERBB2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu
Reactivity
Human, Mouse, Rat
Applications
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extract from HeLa cells untreated or treated with UV using c-Jun (phospho-Thr91) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using c-Jun (phospho-Thr91) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from A2780 cells using cdc25A (Ab-75) antibody and cdc25A (phospho-Ser75) antibody)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using cdc25A (phospho-Ser75) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extract from 293 cells, untreated or treated with insulin (40uM, 30min), using GSK3beta (Ab-216) Antibody and GSK3beta (Phospho-Tyr216) Antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using GSK3beta (Phospho-Tyr216) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extracts from 293 cells using BAD (phospho-Ser155) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using BAD (phospho-Ser155) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
WB (Western Blot) (Western blot analysis of extract from HeLa cells using NF-kappaB p65 (phospho-Ser276) antibody.)
IHC (Immunohistochemistry) (P-Peptide-+ Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using NF-kappaB p65 (phospho-Ser276) antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatogramphy using non-phosphopeptide corresponding to the phosphorylation site.
Pricing
What Are Phospho Antibodies?
Protein phosphorylation is a process where a phosphate group is added to certain amino acid residues of a protein – usually serine (S), threonine (T), or tyrosine (Y) - by enzymes called kinases. This process is integral in controlling cellular signaling, cellular growth, and other biological functions.
Our catalog includes a wide range of phospho-specific antibodies that can accurately detect this important marker. They perform strongly in widely-used laboratory applications such as Western blot, flow cytometry, immunohistochemistry, and immunofluorescence microscopy. We value your trust in us and are committed to providing top-quality products and services. All of our antibodies are guaranteed to work for the applications and species indicated on our website & associated product pages.
What Are The Key Applications of Phospho Antibodies?
1. Western Blotting
One of the first steps a researcher can take in utilizing these phospho-specific antibodies, is to check if the antibody works using a technique referred to as “Western blot”. For those unfamiliar, Western Blot aids in showing whether the protein that the antibody recognizes is appearing at the correct/expected size. These phospho-specific antibodies should also be able to detect changes in the target protein’s phosphorylation (on/off state) when cells are stimulated in certain ways.
2. Staining of Fixed Cells (Immunocytochemistry)
Another routine use of these phospho-specific antibodies, is to test if the antibody is able to demonstrate similar performance when used on fixed cells (intact cells that have been preserved) as it did in the Western blot tests. It is an important aspect in many cases to confirm that the antibody works in actual intact cell samples. Ideally, the method used for cellular fixation should be the same as what is used in pathology labs (like using 10% formalin). To check if the antibody works well in tissue sections (FFPE), researchers will often test it on fixed cells that are processed similar to tissue samples.
3. Specificity Tests Using Peptides
In order to make sure that the antibody is only binding to the right target:
Laboratory technicians will mix the antibody with phospho-peptides (short segments of the protein containing the phosphate group modification).
If the antibody signal disappears, it is confirmation that it is binding to the correct phosphorylated location.
A more robust test is to use both the phosphorylated and non-phosphorylated (dephosphorylated) versions of the protein. The antibody should react only with the phosphorylated one.
Another method sometimes utilized is to treat the sample with an enzyme, such as alkaline phosphatase, that specifically removes phosphate groups. If the antibody signal disappears after this, it also confirms specificity.
4. Genetic Confirmation
As a final step, scientists can genetically manipulate the nucleotide sequence and alter the target protein by removing the exact site where phosphorylation happens. If the antibody no longer appears to detect the modified protein, it is strong evidence supporting the antibody being specific for that phosphorylated site.
Why Buy Phospho Antibodies Through Us?
The production laboratory adheres to strict and consistent protocols prior to releasing any of these phospho-specific antibodies:
Standard methods and proper controls in all tests to ensure high quality.
These antibodies are tested and validated in different cell types and species.
High quality control criterion to ensure each batch is consistent, so you will obtain reliable results every time.
FAQ
1. What Are Phospho-Specific Antibodies?
Phospho-specific antibodies are made to detect proteins only when they have a phosphate group linked to a specific amino acid residue. This empowers scientists understand if a protein is "turned on" or active, based on its phosphorylation state.
2. How to Detect Phosphorylated Proteins in a Western Blot?
To find out if a protein is phosphorylated using Western blot:
Use a phospho-specific antibody that binds only to the phosphorylated form of the protein.
You can also use a “regular” antibody for the same amino acid sequence of the protein that the phospho-specific antibody is binding to (but in this case, this antibody will not bind if there is a phosphate group present) in order to compare how much of it is phosphorylated versus how much is non-phosphorylated (or “total” protein, if the “normal” antibody’s epitopes are non-phospho-site-specific).
3. How to Choose the Best Antibody?
Here are some simple tips to help you pick the right antibody:
Know your target
Match your sample characteristics
Confirm the intended use is appropriate
Check “host” and “type”
Check the “quality” of the presented data/images
Appraise whether the available validation meets your needs
Submit a Question
Please complete the form below and a representative will contact you as soon as possible.
Request more Information
Please complete the form below and a representative will contact you as soon as possible.
Request a Manual
Please complete the form below and a representative will contact you as soon as possible.
Request a Quote
Please complete the form below and a representative will contact you as soon as possible.